Brigitte C Widemann

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors
    Katherine E Warren
    National Cancer Institute Neuro Oncology Branch, Building 82, Room 219, 9030 Old Georgetown Rd, Bethesda, MD 20892 8200, USA
    J Clin Oncol 23:7646-53. 2005
  2. pmc Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1
    Rosa Nguyen
    Department of Neurology, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Orphanet J Rare Dis 7:75. 2012
  3. doi request reprint A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report
    Brigitte C Widemann
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 18:6011-22. 2012
  4. pmc Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome
    Brigitte C Widemann
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892 1101, USA
    J Clin Oncol 28:3979-86. 2010
  5. ncbi request reprint Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors
    Brigitte C Widemann
    Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, Bethesda, MD 20892, USA
    Curr Oncol Rep 11:322-8. 2009
  6. pmc Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group
    Brigitte C Widemann
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
    Pediatr Blood Cancer 56:226-33. 2011
  7. pmc Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors
    Brigitte C Widemann
    Pediatric and Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 27:550-6. 2009
  8. ncbi request reprint Understanding and managing methotrexate nephrotoxicity
    Brigitte C Widemann
    Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, Building 10 CRC Room 1 5750, Bethesda, Maryland 20892 1101, USA
    Oncologist 11:694-703. 2006
  9. ncbi request reprint Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas
    Brigitte C Widemann
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 24:507-16. 2006
  10. ncbi request reprint Merlin PAKs a punch
    Brigitte C Widemann
    Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, Building 10, Room 13C103, Bethesda, Maryland 20892 1928, USA
    Cancer J 10:8-11. 2004

Collaborators

Detail Information

Publications36

  1. ncbi request reprint Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumors
    Katherine E Warren
    National Cancer Institute Neuro Oncology Branch, Building 82, Room 219, 9030 Old Georgetown Rd, Bethesda, MD 20892 8200, USA
    J Clin Oncol 23:7646-53. 2005
    ....
  2. pmc Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1
    Rosa Nguyen
    Department of Neurology, University Hospital Hamburg Eppendorf, Hamburg, Germany
    Orphanet J Rare Dis 7:75. 2012
    ..To examine the natural growth dynamics of internal plexiform neurofibromas (PNs) in patients with neurofibromatosis 1 (NF1)...
  3. doi request reprint A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report
    Brigitte C Widemann
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 18:6011-22. 2012
    ....
  4. pmc Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome
    Brigitte C Widemann
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892 1101, USA
    J Clin Oncol 28:3979-86. 2010
    ..To assess the role of the recombinant bacterial enzyme, glucarpidase (carboxypeptidase-G(2)), leucovorin, and thymidine in the management and outcome of patients with high-dose methotrexate (HDMTX) -induced nephrotoxicity...
  5. ncbi request reprint Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors
    Brigitte C Widemann
    Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, Bethesda, MD 20892, USA
    Curr Oncol Rep 11:322-8. 2009
    ..This knowledge, coupled with the availability of preclinical MPNST models, likely will accelerate the development of effective treatments for this malignancy...
  6. pmc Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology Group
    Brigitte C Widemann
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
    Pediatr Blood Cancer 56:226-33. 2011
    ..The objectives of this trial were to define the toxicity profile, dose, pharmacokinetics, and pharmacodynamics of the farnesyl transferase (FTase) inhibitor, tipifarnib, in children and adolescents with hematological malignancies...
  7. pmc Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors
    Brigitte C Widemann
    Pediatric and Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 27:550-6. 2009
    ....
  8. ncbi request reprint Understanding and managing methotrexate nephrotoxicity
    Brigitte C Widemann
    Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, Building 10 CRC Room 1 5750, Bethesda, Maryland 20892 1101, USA
    Oncologist 11:694-703. 2006
    ..7% (range, 84%-99.5%). The early administration of CPDG(2) in addition to LV may be beneficial for patients with MTX-induced renal dysfunction and significantly elevated plasma MTX concentrations...
  9. ncbi request reprint Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas
    Brigitte C Widemann
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 24:507-16. 2006
    ....
  10. ncbi request reprint Merlin PAKs a punch
    Brigitte C Widemann
    Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, Building 10, Room 13C103, Bethesda, Maryland 20892 1928, USA
    Cancer J 10:8-11. 2004
  11. doi request reprint A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors
    Elizabeth Fox
    Authors Affiliations Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 14:1111-5. 2008
    ..To determine the toxicity profile, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) of ABT-751 administered orally once daily for 21 days, repeated every 28 days in a pediatric population...
  12. doi request reprint The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates
    Aerang Kim
    Pediatric Oncology Branch, Pharmacology and Experimental Therapeutics Section, National Cancer Institute, 10 Center Drive, Building 10 CRC, Bethesda, MD 20892, USA
    Invest New Drugs 30:524-8. 2012
    ..We evaluated the plasma and cerebrospinal fluid (CSF) pharmacokinetics (PK) of sorafenib after an intravenous (IV) dose in a non-human primate (NHP) model...
  13. doi request reprint Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas
    Aerang Kim
    Pediatric Oncology Branch, NCI, CCR, Bethesda, Maryland, USA
    Pediatr Blood Cancer 60:396-401. 2013
    ..Monitoring long-term toxicities such as effects on growth and obtaining additional pharmacokinetic data were of importance due to the young age and long duration of therapy seen in previous phase I trials in children with NF1...
  14. ncbi request reprint Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2
    Brigitte C Widemann
    Pediatric Oncology Branch, Pediatric Oncology Branch, National Cancer Institute, 10 Center Dr, Bldg 10, Rm 13C103, Bethesda, MD 20892 1920, USA
    J Natl Cancer Inst 96:1557-9. 2004
    ..Intrathecal CPDG2 is well tolerated, rapidly decreases CSF methotrexate concentrations, and appears to be efficacious for treating accidental intrathecal methotrexate overdoses...
  15. doi request reprint Characteristics and outcome of pediatric patients enrolled in phase I oncology trials
    Aerang Kim
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, 10 Center Drive, Building 10 CRC, Room 1 3872, Bethesda, MD 20892, USA
    Oncologist 13:679-89. 2008
    ..To describe the characteristics of pediatric subjects who enroll in phase I trials, to determine the associations between pre-enrollment characteristics and the risk for toxicity, and to analyze response and survival outcomes...
  16. doi request reprint The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primates
    Leigh Marcus
    National Cancer Institute, Pediatric Oncology Branch, 10 Center Drive, Building 10 CRC, Room 1 5742, Bethesda, MD 20892 1101, USA
    Cancer Chemother Pharmacol 69:247-52. 2012
    ..7 and 2.6%, respectively). We evaluated the plasma and CSF pharmacokinetics (PK) of satraplatin after an intravenous (IV) dose in NHP...
  17. doi request reprint Conclusions and future directions for the REiNS International Collaboration
    Brigitte C Widemann
    From the Pediatric Oncology Branch B C W, E D, P L W, National Cancer Institute, Bethesda, MD Department of Neurology, Neurosurgery, and Oncology J O B, Johns Hopkins, Baltimore, MD Division of Oncology, Department of Pediatrics M J F, The Children s Hospital of Pennsylvania, Philadelphia Plymouth University Peninsula Schools of Medicine and Dentistry C O H, Plymouth, United Kingdom The Jennifer and Daniel Gilbert Neurofibromatosis Institute K S W, Children s National Medical Center, Washington, DC and Neurology Department and Cancer Center S R P Massachusetts General Hospital, Boston, MA
    Neurology 81:S41-4. 2013
    ..The REiNS Collaboration welcomes anyone interested in providing his or her expertise toward this effort. ..
  18. pmc Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas
    Elizabeth Fox
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
    Clin Cancer Res 15:7361-7. 2009
    ..To compare the effectiveness, tolerance, and pharmacokinetics of a single dose of pegfilgrastim to daily filgrastim in children and young adults with sarcomas treated with dose-intensive combination chemotherapy...
  19. pmc Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma
    Elizabeth Fox
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Blood 111:566-73. 2008
    ..15 mg/kg per day. The response rate in children with relapsed APL is similar to the response rate in adults. This trial was registered as #NCT00020111 at www.ClinicalTrials.gov...
  20. doi request reprint Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma
    Elizabeth Fox
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
    Clin Cancer Res 19:4239-48. 2013
    ..Vandetanib, a VEGF and EGF receptor inhibitor, blocks RET tyrosine kinase activity and is active in adults with hereditary MTC...
  21. ncbi request reprint High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma
    Brigitte C Widemann
    Pediatric Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892 1920, USA
    Cancer 100:2222-32. 2004
    ....
  22. ncbi request reprint A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancer
    Peter F Lebowitz
    Medical Oncology Clinical Research Unit, National Cancer Institute NIH, 9000 Rockville Pike, Bethesda, MD 20892, USA
    Clin Cancer Res 11:1247-52. 2005
    ..We studied the safety and toxicity of tipifarnib in combination with tamoxifen in metastatic breast cancer. The pharmacokinetics and pharmacodynamics of tipifarnib were also assessed...
  23. pmc Automated volumetric growth plate measurement using magnetic resonance imaging for monitoring skeletal toxicity in children treated on investigational drug trials
    Aerang Kim
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 17:5982-90. 2011
    ..Careful evaluation of skeletal toxicity in the clinical development of targeted therapies for children is required. We validated a novel method to measure the growth plate volume using MRI...
  24. ncbi request reprint A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors
    Elizabeth Fox
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 12:4882-7. 2006
    ..To determine the toxicity profile, dose-limiting toxicities, and maximum tolerated dose of ABT-751 administered orally once daily for 7 days, repeated every 21 days...
  25. pmc Experiences of families with a child, adolescent, or young adult with neurofibromatosis type 1 and plexiform neurofibroma evaluated for clinical trials participation at the National Cancer Institute
    Staci Martin
    Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    Contemp Clin Trials 32:10-5. 2011
    ..However, little is known about the experiences of families with children with NF1 participating in clinical trials...
  26. doi request reprint Plasma and CNS pharmacokinetics of O4-benzylfolic acid (O4BF) and metabolite in a non-human primate model
    Meredith K Chuk
    Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, Building 10 Rm 1W 5750, Bethesda, MD 20892, USA
    Cancer Chemother Pharmacol 67:1291-7. 2011
    ..We studied plasma and cerebrospinal fluid (CSF) pharmacokinetics and CSF penetration of O(4)BF in a non-human primate model...
  27. doi request reprint Bone mineral density in children and young adults with neurofibromatosis type 1
    Maya B Lodish
    Section on Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA
    Endocr Relat Cancer 19:817-25. 2012
    ..90; P=0.036). Plexiform neurofibroma burden was negatively correlated with LS BMAD (r(s)=-0.36, P=0.01). In pediatric and young adult patients with NF-1, LS BMAD was more severely affected than the FN BMAD or whole-body BMC/height...
  28. doi request reprint Achieving consensus for clinical trials: the REiNS International Collaboration
    Scott R Plotkin
    From the Neurology Department and Cancer Center S R P, Massachusetts General Hospital, Boston, MA Department of Neurology, Neurosurgery, and Oncology J O B, Johns Hopkins, Baltimore, MD Pediatric Oncology Branch E D, P L W, B C W, National Cancer Institute, Bethesda, MD Division of Oncology, Department of Pediatrics M J F, The Children s Hospital of Pennsylvania, Philadelphia Plymouth University Peninsula Schools of Medicine and Dentistry C O H, Plymouth, United Kingdom and The Jennifer and Daniel Gilbert Neurofibromatosis Institute K S W, Children s National Medical Center, Washington, DC
    Neurology 81:S1-5. 2013
    ..Ultimately, we plan to engage industry partners and national regulatory agencies in this process to facilitate the approval of drugs for patients with NF...
  29. pmc Model for concomitant microdialysis sampling of the pons and cerebral cortex in rhesus macaques (Macaca mulatta)
    Cynthia M McCully
    National Cancer Institute, Bethesda, Maryland, USA
    Comp Med 63:355-60. 2013
    ..This animal model allows for the determination of differences in CNS penetration of chemotherapeutic agents in the pons, cortex, and CSF after systemic drug administration. ..
  30. doi request reprint Recommendations for imaging tumor response in neurofibromatosis clinical trials
    Eva Dombi
    From the Pediatric Oncology Branch E D, B C W, National Cancer Institute, Bethesda, MD Department of Neurology S L A H, The Children s Hospital at Westmead, Sydney, Australia Department of Medical Genetics D B V, Mayo Clinic, Rochester, MN Neurosurgical Service F G B, Department of Radiology G J H, and Department of Neurology and Cancer Center S R P, Massachusetts General Hospital, Boston, MA Department of Neuroradiology S C, King s College Hospital, London, UK Department of Genetic Medicine D G E, MAHSC, St Mary s Hospital, Manchester, UK Division of Oncology M J F and Department of Radiology D J, The Children s Hospital of Philadelphia Department of Pediatrics M J F, The Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA Department of Neurosurgery S G, Hopital Beaujon, Clichy, France Division of Pediatric Hematology Oncology and NYU Cancer Institute M A K, NYU Langone Medical Center, New York, NY Department of Genetics B R K, University of Alabama at Birmingham, Birmingham, AL Department of Neurology V M, University Medical Center Hamburg Eppendorf, Hamburg, Germany Department of Radiology T Y P, Boston Children s Hospital
    Neurology 81:S33-40. 2013
    ....
  31. pmc PET-guided biopsy with needle navigation facilitates diagnosis of angiosarcoma in neurofibromatosis type 1
    Yilun Koethe
    Center for Interventional Oncology, National Institutes of Health, Bethesda, Maryland Radiology and Imaging Sciences, National Institutes of Health, Bethesda, Maryland Duke University School of Medicine, Durham, North Carolina
    Pediatr Blood Cancer 60:E166-9. 2013
    ..Successful targeting assisted treatment selection in this case. This novel navigation technique may facilitate the otherwise difficult diagnosis of malignancy in patients with NF1...
  32. pmc Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumors
    Melinda S Merchant
    National Cancer Institute, National Institutes of Health, 10 Center Dr, Building 10 CRC, Room 1W 3750, Bethesda, MD 20892 1104, USA
    J Clin Oncol 30:4141-7. 2012
    ..Lexatumumab is an agonistic, fully human monoclonal antibody against tumor necrosis factor-related apoptosis-inducing ligand receptor 2 with preclinical evidence of activity in pediatric solid tumors...
  33. ncbi request reprint Evaluation and treatment of fever in the non-neutropenic child with cancer
    Wanda Salzer
    Pharmacology and Experimental Therapeutics Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
    J Pediatr Hematol Oncol 25:606-12. 2003
    ..To document the current approach to the evaluation and treatment of febrile non-neutropenic children with cancer by surveying American Society of Pediatric Hematology/Oncology (ASPHO) members...
  34. ncbi request reprint Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas
    Dusica Babovic-Vuksanovic
    Department of Medical Genetics, Mayo College of Medicine, Rochester, MN, USA
    Pediatr Neurol 36:293-300. 2007
    ..The second dose level was the pharmacokinetically comparable dose and is being used in an ongoing phase II trial of pirfenidone for children with neurofibromatosis 1 and progressive plexiform neurofibroma...
  35. ncbi request reprint The role of [18F]-fluorodeoxyglucose positron emission tomography in predicting plexiform neurofibroma progression
    Michael J Fisher
    Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    J Neurooncol 87:165-71. 2008
    ..We hypothesized that PN tumors with high metabolic activity as demonstrated by FDG-PET are more likely to progress in the following year...
  36. pmc Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1
    Victor F Mautner
    Department of Maxillofacial Surgery, University Hospital Eppendorf, Hamburg, Germany
    Neuro Oncol 10:593-8. 2008
    ..Close surveillance of these high-risk patients may permit earlier diagnosis and more effective treatment of MPNSTs that develop...